OBJECTIVE: Carcinosarcoma is a deadly gynecologic malignancy with few effective treatment options. The study of new therapies is difficult because of its rarity. The objective of this study was to determine the efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma. METHODS: The efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu. Data regarding IC50, cell cycle distribution, and cell signaling changes were assessed by flow cytometry. The efficacy of neratinib was determined in treating mice harboring HER2 amplified carcinosarcoma xenografts. RESULTS: Two of seven (28.5%) carcinosarcoma cell lines were HER2/neu amplified. HER2/neu amplified cell lines SARARK6 and SARARK9 were significantly more sensitive to neratinib than the five non-HER2/neu amplified carcinosarcoma cell lines (mean±SEM IC50:0.014μM±0.004vs.0.164μM±0.019 p=0.0003). Neratinib treatment caused a significant build up in G0/G1 phase of the cell cycle, arrest auto phosphorylation of HER2/neu and activation of S6. Neratinib inhibited tumor growth (p=0.012) and prolonged survival in mice harboring HER2 amplified carcinosarcoma xenografts (p=0.0039). CONCLUSIONS: Neratinib inhibits HER2 amplified carcinosarcoma proliferation, signaling, cell cycle progression and tumor growth in vitro. Neratinib inhibits HER2/neu amplified xenograft growth and improves overall survival. Clinical trials are warranted.
OBJECTIVE:Carcinosarcoma is a deadly gynecologic malignancy with few effective treatment options. The study of new therapies is difficult because of its rarity. The objective of this study was to determine the efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma. METHODS: The efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu. Data regarding IC50, cell cycle distribution, and cell signaling changes were assessed by flow cytometry. The efficacy of neratinib was determined in treating mice harboring HER2 amplified carcinosarcoma xenografts. RESULTS: Two of seven (28.5%) carcinosarcoma cell lines were HER2/neu amplified. HER2/neu amplified cell lines SARARK6 and SARARK9 were significantly more sensitive to neratinib than the five non-HER2/neu amplified carcinosarcoma cell lines (mean±SEM IC50:0.014μM±0.004vs.0.164μM±0.019 p=0.0003). Neratinib treatment caused a significant build up in G0/G1 phase of the cell cycle, arrest auto phosphorylation of HER2/neu and activation of S6. Neratinib inhibited tumor growth (p=0.012) and prolonged survival in mice harboring HER2 amplified carcinosarcoma xenografts (p=0.0039). CONCLUSIONS:Neratinib inhibits HER2 amplified carcinosarcoma proliferation, signaling, cell cycle progression and tumor growth in vitro. Neratinib inhibits HER2/neu amplified xenograft growth and improves overall survival. Clinical trials are warranted.
Authors: Chad A Livasy; F Catrina Reading; Dominic T Moore; John F Boggess; Ruth A Lininger Journal: Gynecol Oncol Date: 2005-09-12 Impact factor: 5.482
Authors: Hwei-Ru Tsou; Elsebe G Overbeek-Klumpers; William A Hallett; Marvin F Reich; M Brawner Floyd; Bernard D Johnson; Ronald S Michalak; Ramaswamy Nilakantan; Carolyn Discafani; Jonathan Golas; Sridhar K Rabindran; Ru Shen; Xiaoqing Shi; Yu-Fen Wang; Janis Upeslacis; Allan Wissner Journal: J Med Chem Date: 2005-02-24 Impact factor: 7.446
Authors: Carlton L Schwab; Diana P English; Dana M Roque; Stefania Bellone; Salvatore Lopez; Emiliano Cocco; Roberta Nicoletti; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin Journal: Gynecol Oncol Date: 2014-08-12 Impact factor: 5.482
Authors: J Alejandro Rauh-Hain; Elisabeth J Diver; Joel T Clemmer; Leslie S Bradford; Rachel M Clark; Whitfield B Growdon; A K Goodman; David M Boruta; John O Schorge; Marcela G del Carmen Journal: Gynecol Oncol Date: 2013-07-29 Impact factor: 5.482
Authors: Rachel C Jankowitz; Jame Abraham; Antoinette R Tan; Steven A Limentani; Marni B Tierno; Laura M Adamson; Marc Buyse; Norman Wolmark; Samuel A Jacobs Journal: Cancer Chemother Pharmacol Date: 2013-12 Impact factor: 3.333
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Sridhar K Rabindran; Carolyn M Discafani; Edward C Rosfjord; Michelle Baxter; M Brawner Floyd; Jonathan Golas; William A Hallett; Bernard D Johnson; Ramaswamy Nilakantan; Elsebe Overbeek; Marvin F Reich; Ru Shen; Xiaoqing Shi; Hwei-Ru Tsou; Yu-Fen Wang; Allan Wissner Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: Gulden Menderes; Elena Bonazzoli; Stefania Bellone; Jonathan D Black; Salvatore Lopez; Francesca Pettinella; Alice Masserdotti; Luca Zammataro; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin Journal: Med Oncol Date: 2017-04-10 Impact factor: 3.064
Authors: Elena Ivanova; Mari Kuraguchi; Man Xu; Andrew J Portell; Luke Taus; Irmina Diala; Alshad S Lalani; Jihyun Choi; Emily S Chambers; Shuai Li; Shengwu Liu; Ting Chen; Thanh U Barbie; Geoffrey R Oxnard; Jacob J Haworth; Kwok-Kin Wong; Suzanne E Dahlberg; Amir A Aref; David A Barbie; Magda Bahcall; Cloud P Paweletz; Pasi A Jänne Journal: Clin Cancer Res Date: 2020-02-07 Impact factor: 12.531